Concepedia

Verna Hillsamer

VH

4

Publications

74

Citations

4

H-Index

2000

Active since

Affiliations

Johnson & Johnson (United States)(Current)

Janssen (Belgium)

Verna Hillsamer is an author at Johnson & Johnson (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2000–2012

4

Publications

4

Impact of gavage dosing procedure and gastric content on adverse respiratory effects and mortality in rat toxicity studies

Gary Eichenbaum, S Damsch, Adriana Looszova et al. · Journal of Applied Toxicology · 2010 · 29 citations

, , +16

Nonclinical Safety Assessment of a Synthetic Peptide Thrombopoietin Agonist

Elaine Knight, Gary Eichenbaum, Verna Hillsamer et al. · International Journal of Toxicology · 2011 · 18 citations

Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti‐MRSA fluoroquinolone JNJ‐Q2

Gary Eichenbaum, M Pugsley, DJ Gallacher et al. · British Journal of Pharmacology · 2012 · 15 citations · Full text

Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341.

Jim Wright, Verna Hillsamer, Robert E. Gore‐Langton et al. · PubMed · 2000 · 12 citations

, , +6

Rows per page

1–4 of 4